Advances in subcutaneous infusion pump therapy for PAH

Aug 24

1 min read

Infusion pump technology for subcutaneous prostacyclin analog therapy has improved, with improved user experiences, simplified priming processes, easier filling, capability for lower doses, and better safety alerts and alarms. This may allow more pulmonary arterial hypertension (PAH) patients to safely manage and benefit from subcutaneous prostacyclin analogs.

Read the Advances in Therapy commentary

Recent Posts

First two patients enrolled in a clinical trial to treat Group 2 PH

A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is min

Animal research shows miR-224 contributes to PAH

A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that

Dual PH therapy before BPA lowers complications

Researchers found that pre-treating pulmonary hypertension (PH) patients with dual therapy before they underwent balloon pulmonary angioplasty was associated with lower complications and better clinic

Comments